XOMA Royalty Corp.

NASDAQ:XOMA

Biotechnology

Healthcare
$40.17 +0.44%

+$0.19 today

Market cap
$503.77M
Beta
0.87
P/E (TTM)
15.8
EPS (TTM)
$2.65
52W Low $22.29High $42.81

Volume 4.22M

Average 0.21M

XOMA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

XOMA Royalty Corp.NASDAQ: XOMA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 92.7%

Gross margin was 92.7% in Q1 FY2026, down 3.8 pp from a year earlier. On a trailing-twelve-month basis it was 93.3%, down 0.8 pp year over year. Over 3 fiscal years it narrowed by 1.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
92.7%-7.3 pp QoQ
Last fiscal yearDec 2025
94.3%-5.0 pp YoY
LTMMar 2026
93.3%-0.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.8 pp——
1 year-5.0 pp——
3 years-1.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
94.3%
Year-over-year change
-5.0pp

Gross Margin vs competitors

How XOMA compares with its peers on the latest reported figures

  • XOMA's LTM Mar 2026 gross margin of 93.3% is the highest of the 3 companies compared; the peer median is 14.4%.
  • Its year-over-year change of -0.8 pp is the 2nd highest of 3, against a peer median of +811.8 pp.
  • Over three fiscal years its change of -1.2 pp compares with a peer median of -127.8 pp.
XOMA Competitors Peer median
Gross Margin for XOMA and competitors
Company Period LTM level YoY 3-year change
XOMAXOMA Royalty Corp.LTM Mar 202693.3% -0.8 pp-1.2 pp
QSIQuantum-Si incorporatedLTM Mar 202640.0% -12.8 pp—
AUTLAutolus Therapeutics plcLTM Mar 2026-11.2% +1636.4 pp-127.8 pp
DSGNDesign Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
AURAAura Biosciences, Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
DMACDiaMedica Therapeutics Inc.FY2025— ——
BNTCBenitec Biopharma Inc.FY2025— ——
GALTGalectin Therapeutics Inc.FY2025— ——
Peer median (excluding XOMA) 14.4%+811.8 pp-127.8 pp

Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.16M6.03M4.76M28.49M52.15M
Cost of Revenue171K274K143K206K2.96M
Gross Profit37.99M5.75M4.62M28.28M49.18M
Gross Margin99.6%95.5%97.0%99.3%94.3%
Research & Development171K153K143K2.88M1.71M
Selling, General & Admin20.46M23.19M27.18M34.48M36.09M
Operating Expenses20.46M23.17M46.46M68.26M37.79M
Depreciation & Amortization167K274K900K216K2.97M
EBITDA16.52M(16.85M)(22.56M)(5.42M)47.82M
EBITDA Margin43.3%-279.5%-474.2%-19.0%91.7%
Operating Income17.53M(17.41M)(41.85M)(39.98M)11.38M
Operating Margin45.9%-288.9%-879.5%-140.3%21.8%
Interest Income0694K000
Interest Expense461K0569K13.84M13.03M
Other Income / Expenses(1.64M)295K1.02M20.5M20.43M
Income Before Tax15.89M(17.12M)(40.83M)(19.48M)31.82M
Pre-Tax Margin41.6%-284.0%-858.2%-68.4%61.0%
Income Tax Expense91K(15K)0(5.66M)103K
Net Income15.8M(17.1M)(40.83M)(13.82M)31.71M
Net Margin41.4%-283.8%-858.2%-48.5%60.8%
EPS (Basic)0.69(1.98)(4.04)(1.65)1.53
EPS (Diluted)0.65(1.98)(4.04)(1.65)1.46
Weighted Avg Shares11.29M11.41M11.47M11.7M17.98M
Weighted Avg Shares (Diluted)12.19M11.41M11.47M11.7M17.98M

XOMA Royalty Corp.

NASDAQ:XOMA

Intrinsic Alpha fair value

Locked

Current Price

$40.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.